 PRINCETON, N.J., June 22, 2021 PRNewswire -- Soligenix, Inc. Nasdaq: SNGX Soligenix or the Company, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the University of Pennsylvania, and the Lead Principal Investigator for the Phase 3 FLASH Fluorescent Light Activated Synthetic Hypericin study in cutaneous T-cell lymphoma CTCL, will present key details of HyBryteTM hypericin ointment 0.25 efficacy and safety profile demonstrated in the FLASH study at the United States Cutaneous Lymphoma Consortium USCLC Annual Meeting, to be held on June 26, 2021. 